Navigation Links
LSUHSC awarded patent for compound inhibiting cancer and other diseases
Date:10/6/2008

New Orleans, LA Dr. Eugene Woltering, the James D. Rives Professor of Surgery and Neurosciences at LSU Health Sciences Center New Orleans School of Medicine, and Dr. Conrad Hornick, former LSUHSC Professor of Physiology, have been awarded a US Patent for a compound to inhibit the formation of blood vessels critical to the growth of cancerous tumors and diseases like diabetic retinopathy, obesity, and psoriasis.

Apolipoprotein A-I is the major protein component of lipoproteins water soluble carrier molecules that transport cholesterol through the blood. LSUHSC researchers discovered that it can be used to destroy existing blood vessels as well as prevent the development of new vessels. For a tumor to grow bigger than 2 mm, the diameter of a large grain of sand, it must a have blood supply. Application of Apoliporpotein A-1 and high density lipoprotein has been proven effective in inhibiting tumor growth dependent upon angiogenesisthe process of developing new blood vessels. Studies have demonstrated that the level of vascularization in a tumor is strongly associated with metastasis in melanoma, breast, and lung carcinomas.

"This patent was based on the observation that lipid droplets are critical to the formation of the lumen of the blood vessels. By removing these fat droplets from the developing blood vessel we feel that we will be able to control the growth of new blood vessels that would feed tumors," notes Dr. Woltering.

There is also evidence that Apolipoprotein A-1 will be effective in treating other diseases reliant upon angiogenesis. In those diseases, angiogenesis is the root cause of tissue injury, including blindness associated with proliferative retinopathies, skin disorders such as psoriasis, and rheumatoid arthritis. Diseases that have been associated with abnormal blood vessel formation include Crohn's disease, diabetic retinopathy, macular degeneration, obesity, corneal neovascularization, benign tumors, hemangioma, arterial/venous malformations, sickle cell anemia, sarcoidosis, syphilis, pseudoxanthoma elasticum, Pagets disease, vein occlusion in the eye, infections of the retina, hyperparathyroidism, carotid obstructive disease, chronic uveitis/vitritis, mycobacterial infections, Lyme disease, systemic lupus erythematosis, psoriasis, myopia, optic pits, Stargarts disease, chronic retinal detachment, hyperviscosity syndrome, toxoplasmosis, trauma, rheumatoid arthritis, and post-laser complications.


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-452-9166
Louisiana State University Health Science Center
Source:Eurekalert

Related biology news :

1. LSUHSC awarded $10M+ COBRE grant
2. LSUHSCs Lazartigues awarded $1.2 million grant
3. LSUHSC research reports new method to protect brain cells from diseases like Alzheimers
4. 12 McGill researchers awarded Canada Research Chairs
5. Anthony S. Fauci awarded Lasker Award for Public Service
6. ETH Zurich professor Ari Helenius awarded Benoist Prize
7. Nanobiosym awarded $2 million DTRA contract
8. Mustafa alAbsi Ph.D. and national team awarded major NIH grant
9. Parus Interactive Awarded Patent for Speech-Activated Remote System Management
10. $2.7 million awarded for metastatic colon cancer research
11. UCR researchers awarded nearly $1.7M to develop improved cowpea varieties
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:3/30/2017)...  On April 6-7, 2017, Sequencing.com will host the ... hackathon at Microsoft,s headquarters in Redmond, Washington ... developing health and wellness apps that provide a unique, ... is the first hackathon for personal genomics and ... in the genomics, tech and health industries are sending ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... ... Personal eye wash is a basic first aid supply for any work environment, but most ... you rinse first if a dangerous substance enters both eyes? It’s one less decision, and ... unique dual eye piece. , “Whether its dirt and debris, or an acid or alkali, ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published ... frozen and fresh in vitro fertilization (IVF) transfer cycles. The multi-center ... success. , After comparing the results from the fresh and frozen transfer cohorts, ...
Breaking Biology Technology: